Q/C Technologies Files 8-K with Bylaw Amendments
Ticker: QCLS · Form: 8-K · Filed: Sep 26, 2025 · CIK: 1321834
| Field | Detail |
|---|---|
| Company | Q/C Technologies, Inc. (QCLS) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, financial-reporting, bylaws
TL;DR
QC Tech filed an 8-K on 9/22, updating bylaws and financials. Formerly MyMD.
AI Summary
On September 22, 2025, Q/C Technologies, Inc. filed an 8-K report detailing amendments to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and financial statements. The company, formerly known as TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., and Akers Biosciences, Inc., is incorporated in Delaware and has its fiscal year end on December 31st. The filing was made on September 26, 2025.
Why It Matters
This 8-K filing indicates potential changes in the company's governance structure and regulatory compliance, which could impact its operational direction and investor relations.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting amendments and financial statements, with no immediate indication of significant financial distress or operational disruption.
Key Players & Entities
- Q/C Technologies, Inc. (company) — Registrant
- September 22, 2025 (date) — Date of earliest event reported
- September 26, 2025 (date) — Filing date
- TNF Pharmaceuticals, Inc. (company) — Former company name
- MyMD Pharmaceuticals, Inc. (company) — Former company name
- Akers Biosciences, Inc. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- December 31 (date) — Fiscal year end
FAQ
What specific amendments were made to Q/C Technologies, Inc.'s Articles of Incorporation or Bylaws?
The filing indicates amendments to Articles of Incorporation or Bylaws were made, but the specific details of these amendments are not provided in the excerpt.
What is the significance of the Regulation FD disclosure mentioned in the filing?
A Regulation FD disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure to certain investors.
When was Q/C Technologies, Inc. previously known as TNF Pharmaceuticals, Inc.?
The filing does not specify the exact date of the name change from TNF Pharmaceuticals, Inc., only that it is a former company name.
What is the company's fiscal year end?
Q/C Technologies, Inc.'s fiscal year ends on December 31st.
What are the main items reported in this 8-K filing?
This 8-K filing reports amendments to Articles of Incorporation or Bylaws, a Regulation FD disclosure, and financial statements.
Filing Stats: 839 words · 3 min read · ~3 pages · Grade level 10 · Accepted 2025-09-26 17:10:36
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share QCLS The Nasdaq Capital M
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex3-1.htm (EX-3.1) — 17KB
- ex99-1.htm (EX-99.1) — 11KB
- ex99-2.htm (EX-99.2) — 13KB
- 0001493152-25-015774.txt ( ) — 257KB
- tnfa-20250922.xsd (EX-101.SCH) — 3KB
- tnfa-20250922_lab.xml (EX-101.LAB) — 33KB
- tnfa-20250922_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Q/C TECHNOLOGIES, INC. Date: September 26, 2025 By: /s/ Joshua Silverman Name: Joshua Silverman Title: Executive Chairman